LGND up +3.79% percent right now. $LGND High is at 57.88

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 12:53 PM

LGND up +3.79% percent right now. $LGND High is at 57.88 and the Low 55.60 with current volume of 171,280.

Recent News posted below.

LGND Ligand Pharmaceuticals Inc Recent Headline News

Shares of LGND Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - 2 hrs 30 mins ago
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 4 weeks, Ligand Pharmaceuticals has returned 13.91% as of today's recent price of $55.64.
LGND: 58.05 (+2.37)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), ACHN: 13.16 (+0.31), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST

JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), ACHN: 13.16 (+0.31), CNAT: 7.08 (+0.02), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)

Post Earnings Update: Ligand Pharmaceuticals Has Sunk 0.5% Lower in Past 2 Weeks (LGND)
Comtex SmarTrend(R) - Mon Nov 10, 11:52AM CST
When Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings 14 days ago on October 27th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $14.9 million. The company actually reported EPS of $0.06 on sales of $15.0 million, missing EPS estimates by $0.27 and matching revenue estimates. Shares of Ligand Pharmaceuticals have slipped from $54.23 to $53.94, representing a loss of 0.5%, since the company reported earnings 14 days ago.
LGND: 58.05 (+2.37)

Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST

JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)

Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST

JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)

Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST

JNJ: 108.87 (+0.05), GILD: 108.64 (+1.62), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)

Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST

JNJ: 108.87 (+0.05), GILD: 108.66 (+1.64), ACHN: 13.16 (+0.31), CNAT: 7.08 (+0.02), MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), RGLS: 20.38 (-0.53), ABBV: 63.99 (+0.20), BMY: 58.92 (+0.11), ENTA: 43.43 (-0.71)

Ligand Pharmaceuticals Shares Up 12.9% Since SmarTrend's Buy Recommendation (LGND)
Comtex SmarTrend(R) - Mon Nov 03, 10:02AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 2 weeks, Ligand Pharmaceuticals has returned 12.89% as of today's recent price of $55.14.
LGND: 58.05 (+2.37)

Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 326.16 (-1.71), LGND: 58.05 (+2.37), AMGN: 163.23 (+0.14), GSK: 45.80 (+0.64)

Ligand Pharmaceuticals Has Rich A Valuation Now But Is Undervalued For Long Term Success
Chris Katje - at Seeking Alpha - Wed Oct 29, 10:34AM CDT

PFE: 30.21 (+0.01), AZN: 74.26 (+1.05), LGND: 58.05 (+2.37), AMGN: 163.23 (+0.14), GSK: 45.80 (+0.64)

Update: Ligand Posts Consecutive Earnings Beat
Trevor Lowenthal - at Seeking Alpha - Tue Oct 28, 3:21PM CDT

LGND: 58.05 (+2.37)

Ligand Pharmaceuticals' (LGND) CEO Steve Holmes on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Oct 27, 1:56PM CDT

LGND: 58.05 (+2.37)

Ligand Pharmaceuticals reaffirms full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:31AM CDT

LGND: 58.05 (+2.37)

Ligand beats Street 3Q forecasts
Automated Insights - Mon Oct 27, 7:16AM CDT
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Monday reported third-quarter net income of $1.3 million.
LGND: 58.05 (+2.37)

Ligand Pharmaceuticals beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 7:07AM CDT

LGND: 58.05 (+2.37)

Ligand Reports Third Quarter 2014 Financial Results
Business Wire - Mon Oct 27, 7:01AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2014, and provided an operating forecast and program updates.
LGND: 58.05 (+2.37)

Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Oct 26, 4:30PM CDT

ROP: 157.25 (-1.28), SIR: 24.19 (-0.05), VNDA: 12.80 (+0.64), STX: 61.63 (-0.14), NMM: 13.62 (-0.02), LGND: 58.05 (+2.37), PDS: 7.90 (+0.14), TREX: 43.98 (-0.03), EXAS: 22.61 (+0.01), AWI: 49.18 (+0.01), EDR: 11.55 (-0.07), HUN: 25.02 (+0.09), TEN: 53.21 (-0.23), AGN: 195.91 (+0.67), ONB: 14.86 (-0.05), STNG: 8.77 (+0.13), MRK: 59.55 (+0.74), BEN: 56.83 (+0.26)

Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:20PM CDT
Pfizer (PFE) is scheduled to report third-quarter 2014 results before the opening bell on Oct 28.
VRTX: 117.47 (+0.53), PFE: 30.21 (+0.01), LGND: 58.05 (+2.37), TEVA: 58.55 (+0.51)

Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:10PM CDT
Merck & Co. Inc. (MRK) is scheduled to report third-quarter 2014 results before the opening bell on Oct 27.
MRK: 59.55 (+0.74), LGND: 58.05 (+2.37), TEVA: 58.55 (+0.51)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Ping An's Bold Green Moves Ahead of APEC 2026

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Swanson Nexus Pro Launch: Boost for Dietitians

By Lucas Young Updated Oct 24, 2026 Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...